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Summary The aim of this study was to assess by a stepwise multivariate discriminant analysis the value of
four current serum tumour markers - carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 50 and CA
242 and tissue polypeptide antigen (TPA) - and a new serum tumour marker, tissue polypeptide specific
antigen (TPS), in the diagnosis ofpancreatic cancer. The serum values were measured in a prospective series of
patients with jaundice, with unjaundiced cholestasis and with a suspicion of chronic pancreatitis or a
pancreatic tumour (n = 193). There were 24 patients with a cancer of the pancreas and two patients with a
cancer of the papilla of Vater in this series. Our results showed that CA 50 (P<0.001) and TPA (P<0.01)
were the best marker tests in predicting pancreatic malignancy. Also, the TPS (P = 0.07) and CA 242
(P = 0.08) tests showed marginally significant independent discriminating power, while the CEA test did not
(P = 0.12). In order to sum up the contributions of different markers, a diagnostic score (DS1) was developed.
The discrimination function was: DS1 = CA 50 x 1.75 + TPA x 0.62 + TPS x (-0.37) + CA 242 x (- 1.21).
The sensitivity of DS1 in detecting pancreatic cancer was 36% with a specificity of 90% and an efficiency of
82%. When the combination of CA 50 and TPA was used as a test, the discrimination function (DS2) was:
DS2 = CA 50 x 0.69 + TPA x 0.67. The sensitivity of DS2 was 44% with a 88% specificity and an efficiency
of 82%. According to this analysis, the further advantage gained by a computer-aided scoring system seems to
be limited, since despite the considerably high specificity and efficiency its sensitivity remained low. In the
present analysis the best combination in diagnosing pancreatic cancer was the combination of CA 50 and
TPA.
The production of monoclonal antibodies by hybridoma
technology (Kohler & Milstein, 1975) has been a new begin-
ning for the development of monoclonal antibodies to
cancer. Tumour markers are applied clinically in the follow-
ing ways: (1) to study the biology of cancer, (2) to aid in
diagnosis of cancer, (3) to determine the prognosis of cancer
and (4) to monitor the progress of patients with cancer.
In the diagnosis of human pancreatic cancer, several serum
tumour-associated antigens have been studied intensively
during the past decade (Haglund et al., 1987; Benini et al.,
1988; Masson et al., 1990; Haglund et al., 1992; Tian et al.,
1992). In many studies large numbers of markers have been
tested separately, mostly by single-factor analyses, with vary-
ing cut-off levels and in varying patient populations. For
these reasons, evaluation of these studies is often difficult.
Furthermore, according to many previous studies, it is
obvious that the combined use of many similar marker tests
is unreasonable from the clinical or economic point of view
(Haglund et al., 1986; Benini et al., 1988; Pasanen et al.,
1992). Therefore, it would be most desirable to know the
independent diagnostic value of each marker test to find out
the best combination of different tests in diagnosing pan-
creatic cancer. Based on these aspects, we decided to carry
out a multivariate discriminant analysis of the five current
serum tumour markers - carcinoembryonic antigen (CEA),
monoclonal carbohydrate antigen CA 50 and CA 242, tissue
polypeptide antigen (TPA) and tissue polypeptide specific
antigen (TPS) - in the diagnosis of pancreatic cancer.
Materials and methods
The study population consisted of all consecutive jaundiced
and/or cholestatic patients admitted to or attending Kuopio
University Hospital during the 21 year period from the begin-
ning of December 1985 to the end of May 1988. The limits
for inclusion to the study were defined as follows: a serum
bilirubin level exceeding 40 ftmol 1' (normal value in our
laboratory <17jimol 1') and/or serum alkaline phosphatase
level above 350 IU I` (normal value in our laboratory
<210 U 1-') in relation to serum gamma-glutamyltrans-
peptidase level above 100 IU 1` (normal value in our
laboratory <32 U I`), or liver-specific alkaline phosphatase
elevated. In addition to these jaundiced or cholestatic
patients the following patients were included: patients with a
history of two or more episodes of acute pancreatitis,
patients who had continuous or recurring abdominal pain
with raised serum or urine amylase levels measured at least
three times, patients who had been suspected of having a
pancreatic tumour or chronic pancreatitis in ultrasound or
computed tomography examination. Excluded were patients
satisfying any of the following criteria: age less than 15 years,
pregnancy, jaundice developing in the intensive care unit, a
history of recent heart surgery, insufficient cooperation, acute
alcoholic pancreatitis, disseminated malignancy, parenchymal
liver disease diagnosed within 2 days of admission, need for
emergency surgery.
A clinical assessment with routine laboratory tests was
made of all patients on admission to hospital. Complemen-
tary and more detailed laboratory tests were made on all
patients the day after admission to the hospital, including a
wide variety of hepatobiliary laboratory tests and serological
tests. If the clinical assessment raised the suspicion of extra-
hepatic obstruction, ultrasound, computed tomography and
endoscopic retrograde cholangiopancreatography were per-
formed as described previously (Pasanen et al., 1991). If
within 2 days after entering the study the patient's disease
seemed most likely to be of hepatocellular origin, no imaging
studies were made, but liver biopsy was obtained instead.
The secretin-caerulein test was performed if chronic pan-
creatitis was suspected.
All the patients involved in the study were scheduled for
re-examination 6 months after entering the study, and the
clinical data of the hospital records were reviewed retrospec-
tively after a follow-up period of 2 years. The final diagnosis
of a pancreatic cancer or cancer of the papilla of Vater was
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based on histology in 16 cases, on cytology in three cases, on
operative or endoscopic macroscopic morphological findings
in three cases and on the imaging methods in four cases. The
diagnosis of chronic pancreatitis was based on histology in
seven cases, on cytology in one case, on the secretin-
caerulein test in six cases, on the imaging methods in 14 cases
and on clinical course of the disease in six cases.
The sera of all 193 patients were available for the CEA,
CA 50 and CA 242 measurements. Of these, 113 patients
were jaundiced and 20 had the labroatory values suggesting
unjaundiced cholestasis; 60 patients were studied according
to the criterion of the suspicion of chronic pancreatitis or a
pancreatic tumour. There were altogether 24 patients with
the final diagnosis of carcinoma of the head of the pancreas
and two patients with the diagnosis of carcinoma of the
papilla of Vater. The patient material has previously been
described in detail (Pasanen et al., 1992). The sera of two
patients from that series (two cases of common duct stones)
were missing for TPS analysis, and the sera of 20 patients
were missing for TPA analysis (one pancreatic carcinoma,
four cases of acute and two of chronic pancreatitis, nine
cases of benign hepatobiliary diseases, three cholangiocar-
cinomas and one case of Hodgkin's disease).
Assays
Serum samples were obtained by venipuncture on the patient's
admission to hospital before surgery or biopsy and all serum
samples were stored frozen (- 20°C) until analysed. Serum
CEA concentrations were determined by using monoclonal
antibody in the delayed immunofluorescence technique (TR-
FIA, Wallac, Turku, Finland). Serum CA 50 concentrations
were determined by using monoclonal antibody (C-50) in the
delayed immunofluorescence technique (TR-FIA, Wallac).
Serum CA 242 concentrations were determined by using a
dissociation-enhanced lanthidine fluoroimmunoassay pro-
totype kit (DELFIA; Pharmacia Diagnostics, Uppsala,
Sweden, 1988). Serum TPS concentrations were determined
by using enzyme-linked immunosorbent assay (ELISA, Beki
Diagnostics, Bromma, Sweden). Serum TPA determination
was performed by a radioimmunoassay (RIA) procedure
(Prolifigen RIA kit, AB Sangtec Medical, Bromma,
Sweden).
Statistics
All the gathered data were entered into a VAX computer and
analysed by using the SAS program (Statistical Analysis
System, SAS, Cary, USA). The differences between groups
were analysed by Wilcoxon's non-parametric test. The diag-
nostic accuracy of marker tests was evaluated in terms of
sensitivity (sen), specificity (spe), predictive value (PV),
efficiency (eff) and likelihood ratios (LR) (Albert, 1982;
Feinstein, 1985). The cut-off levels were determined by per-
forming a receiver operating characteristic (ROC) curve
analysis for each marker test (Feinstein, 1985; Pasanen et al.,
1993). A multivariate stepwise discriminant analysis was car-
ried out to study the independent diagnostic value of each
marker test and to find the best combination of the different
tests in predicting pancreatic malignancy (Goldberg & Ellis,
1978).
Results
The serum values (median, interquartile range) of CEA, CA
50, CA 242, TPA and TPS in pancreatic cancer and in
patients with benign hepatopancreatobiliary diseases are
shown in Table I. The differences between these patient
groups were highly significant for all marker tests (Table
I).
The diagnostic accuracy of each marker test in pancreatic
cancer is summarised in Table II. When the optimal cut-off
level for each test was sought by a ROC curve analysis, all
marker tests except TPS reached considerably high efficiency,
the CA 50 test being the best one (83%). Also the LR + of
CA 50 (4.8) was highest (that is, the probability of a correct
positive test result in patients with pancreatic cancer is 4.8
times higher than in those without cancer).
In a multivariate stepwise discriminant analysis, the CA 50
test showed the strongest (P<0.001) diagnostic value. Also,
the TPA test proved to be a significant (P<0.01) indepen-
dent predictor of pancreatic malignancy, while the TPS and
CA 242 tests showed only marginally significant independent
diagnostic value (P = 0.07 and P = 0.08 respectively; Table
III). In order to sum up the contributions of different
markers, a diagnostic score (DS1) was developed. The dis-
Table I Serum concentrations (median, interquartile range) of serum CEA
(ngml-'), CA50 (Uml'), CA242 (Uml-'), TPA (U1-') and TPS (Ul1-) in
patients with pancreatic cancer and benign hepatopancreatobiliary diseases
Benign hepatopancreato-
Pancreatic cancer biliary diseases
Interquartile Interquartile
n Median range n Median range
CEA 26 6.0 3.9-8.9 (149) 2.2 1.6-3.3*
CA 50 26 274.7 128.2-1080.7 (149) 23.5 10.4-83.3*
CA 242 26 113.8 22.3-229.1 (149) 9.2 5.0-16.7*
TPS 26 622 222-1116 (147) 183 98-658*
TPA 25 329 145-404 (134) 103 66-199**
n = number of patients. *P <0.001, **P<0.01, Wilcoxon's test.
Table H Diagnostic accuracy of tumour marker tests CEA, CA 50, CA242,
TPA, TPS and diagnostic scores (DS1 and DS2) in pancreatic cancer (n = 26)
among patients with benign hepatopancreatobiliary diseases (n = 151)
Test sen spe PV+ PV- eff
used (%) (%) (%) (%) (%) LR + LR -
CEA 77 83 42 96 82 4.5 0.3
CA 50 77 84 43 96 83 4.8 0.3
CA 242 81 81 40 96 81 4.2 0.3
TPA 52 85 37 91 80 3.4 0.6
TPS 50 70 21 90 67 1.7 0.7
DSI 36 90 38 89 82 3.4 0.6
DS2 44 88 38 90 82 3.4 0.6
Cut-off levels: CEA, 4.1 ngml-'; CA 50, 137 Uml'; CA 242, 21 Uml'; TPA,
320 Ul-; TPS, 630UI-'.564 P.A. PASANEN et al.
Table III The coefficients of the multivariate model and statistical
significance levels of the tumour markers CEA, CA 50, CA 242, TPS
and TPA in predicting pancreatic cancer
Tumour marker test Coefficient P-value
CA 50 1.75 0.0004
TPA 0.62 0.0016
TPS -0.37 0.072
CA 242 - 1.21 0.080
CEA 0.29 0.12
crimination function was: DSI = CA 50 x 1.75 + TPA x
0.62 + TPS x (-0.37) + CA 242 x (- 1.21). The sensitivity
of DSl in detecting pancreatic cancer was 36% with a
specificity of 90% and an efficiency of 82% (Table II). When
the combination of the two best markers, i.e. that of CA 50
and TPA, was used as a test, the discrimination function
(DS2) was: DS2 = CA 50 x 0.69 + TPA x 0.67. The sensi-
tivity of DS2 was 44% with a 88% specificity and an
efficiency of 82%. The post-test probability of malignant
disease for DS2 was 38%, and the LR + was 3.4 and LR -
0.63 (Table II).
Correlations between the marker tests are shown in Table
IV. In the patients with pancreatic cancer, there was a
significant positive correlation between CEA and TPS
(r = 0.49, P = 0.01), and between CA 50 and CA 242
(r = 0.98, P = 0.0001). All other markers showed non-
significant correlations (Table IV). In benign hepatopan-
creatobiliary diseases, TPA showed a significant positive
correlation with all other markers, and there was also a
significant positive correlation between CA 50 and CA 242
(r = 0.89, P = 0.0001, Table IV).
Discussion
In order to gain more insight into the complex issue of the
use of serum tumour markers in the diagnosis of pancreatic
cancer, we have recently stressed the usefulness of ROC
curve analysis (Pasanen et al., 1993). In many medical studies
the use of discriminant analysis has also been seen to be of
great potential for simultaneous testing of the real indepen-
dent value of various diagnostic tests (Goldberg & Ellis,
1978). In this particular study, therefore, we decided to use
both these methods to clarify the diagnostic value and role of
the five current serum tumour markers in the diagnosis of
pancreatic cancer.
The results of the current study showed that all marker
tests except TPS reached considerably similar and high
efficiencies (80-83%, Table II). This confirms previous data
for CEA, CA 50, and CA 242, whereas few data are
available in the literature on the utility of serum TPA assays,
and there are no data regarding TPS assay in the diagnosis
of pancreatic cancer. TPA is a protein produced by rapidly
growing tissues (Bjorklund & Bjorklund, 1957; Bjorklund,
1980). Since the release of this antigen is a function of cell
division, it differs from many other tumour marker tests by
indicating the tumour proliferative rate rather than the
tumour burden (Bjorklund & Bjorklund, 1983). The diagnos-
tic value of TPA has been reported to be slightly inferior to
that of CA 50 (Benini et al., 1988), but a very high sensitivity
(96.4%) has also been reported (Panucci et al., 1985). In our
study, the sensitivity of TPA was clearly lower (52%) than
that of CEA, CA 50 and CA 242, but the specificity of TPA
was highest (85%) of all. However, at high specificity levels
(>0.90) TPA showed unacceptably low sensitivities, while
the CA 242 test performed best. Nevertheless, in the mul-
tivariate analysis, the TPA test proved an independent
predictor of pancreatic malignancy in addition to the CA 50
test. Thus, our results speak for some clinical utility of TPA
despite its considerably low sensitivity. TPS is the M3-specific
epitope of TPA (Bjorklund, 1980; Bjorklund & Bjorklund,
1983), and in theory it might show higher specificity in
patients with pancreatic cancer. In the present multivariate
analysis, TPS showed marginally independent diagnostic
value, but our results showed clearly that the diagnostic
value of TPS is inferior to that of all other markers, even
though its specificity, PV and efficiency were very high.
According to the present analysis, the value of the
computer-aided scoring system based on multiple tests seems
to be limited, since despite the considerable improvement in
specificity the sensitivity remained low (Table II). The multi-
variate analysis revealed that only the CA 50 and TPA tests
showed significant independent diagnostic value, and that the
diagnostic score of these two markers as such was equal to
that of multiple tests. Some explanation for this can be
sought by the correlation analysis. Our results showed that
the CA 50 and CA 242 tests had a high positive correlation
in both the patients with pancreatic cancer and those with
benign disorders (Table IV), supporting the similarity of
these tests, a result that was to be expected on the basis of
previous studies (Haglund et al., 1989; Kuusela et al., 1991).
Further, the CEA, TPA and TPS tests did not show any
significant correlations with CA 50 or CA 242 in pancreatic
cancer, indicating that these tests measure something other
than the monoclonal carbohydrate antigen tests. It is some-
what surprising that TPA showed a significant positive cor-
relation with all other marker tests in benign diseases (Table
IV), which were not proliferative processes, and it fits poorly
with the fact that TPA is a protein produced by rapidly
growing tissues. No good explanation for this can be given,
but elevated TPA levels caused by hepatitis and liver cir-
rhosis have been similarly reported in previous studies
(Bjorklund, 1980; Andriulli, 1985). Interestingly, there was a
significant positive correlation between the CEA and TPS
concentration in the patients with pancreatic cancer, and
between CEA and TPA in the patients with benign
hepatopancreatobiliary diseases (Table IV).
In conclusion, the further advantage gained by a
Table IV The correlation coefficients (Pearson's r) between the tumour markers CEA, CA 50, CA 242,
TPA and TPS in pancreatic cancer and in benign hepatopancreatobiliary diseases
Pancreatic cancer Benign hepatopancreatobiliary
(n = 26) diseases (n = 151)
Pearson's r P-value Pearson's r P-value
CEA and CA 50 0.03 0.88 0.006 0.93
CEA and CA 242 0.008 0.96 0.02 0.83
CEA and TPA 0.27 0.18 0.26 0.002
CEA and TPS 0.49 0.01 0.03 0.72
CA 50 and CA 242 0.98 0.0001 0.89 0.0001
CA 50 and TPA - 0.005 0.98 0.38 0.0001
CA 50 and TPS - 0.009 0.97 0.10 0.20
CA 242 and TPA - 0.02 0.93 0.38 0.0001
CA 242 and TPS - 0.03 0.90 0.02 0.78
TPA and TPS 0.35 0.08 0.70 0.0001SERUM MARKERS CEA, CA 50, CA 242, TPA AND TPS IN PANCREATIC CANCER 565
computer-aided scoring system based on multiple tests seems
to be limited, and the use of several marker tests with similar
antigenicity gives only little further benefit, whereas combina-
tions of different kinds of markers may give more fruitful
additional information. The best combination of these serum
tumour marker tests in predicting pancreatic malignancy is
the combination of CA 50 and TPA.
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